AIDS and HIV vaccines

Vaccine

Volumn 17, Issue SUPPL. 2, 1999, Pages

  Klein, Michel ^a  

^a 1541 Ave Marcel Merieux 69280 ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CELLULAR IMMUNITY; CONFERENCE PAPER; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; IMMUNE RESPONSE; PRIORITY JOURNAL;

AIDS VACCINES; CLINICAL TRIALS; HIV; HIV ANTIBODIES; HUMANS;

EID: 0033214964     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(99)00236-4     Document Type: Conference Paper

References (50)

1. Heilman C.A., Baltimore D. HIV vaccines - where are we going. Nat. Med. 4:1998;532-534.
2. Heyward W.L., MacQueen K.M., Goldenthal K.L. HIV vaccine development and evaluation: Realistic expectations. AIDS Res Hum Retrovir. 14:(Suppl. 3):1998;S205-S210.
3. Francis D.P., et al. Advancing AIDSVAX to Phase 3. Safety, immunogenicity and plans for Phase 3. AIDS Res. Hum. Retrovi. 14:(Suppl. 3):1998;S325-S331.
4. Almond N.M., Heeney J.L. AIDS vaccine development in primate models. AIDS. 12:(Suppl. A):1998;S133-S140.
5. Boyer J., et al. Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination. Nat. Med. 3:1998;526-532.
6. Lubech M.D., et al. Long-term protection of chimpanzees against high-dose HIV-1 challenge induced by immunization. Nat. Med. 3:1998;651-658.
7. Haigwood N.L., Zolla-Pazner S. Humoral immunity to HIV, SIV and SHIV. AIDS. 12:(Suppl. A):1998;S121-S132.
8. Johnson R.P., Silicano R.F., McElrath M.J. Cellular immune responses to HIV-1. AIDS. 12:(Suppl. A):1998;S113-S120.
9. Trkola A., et al. Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG. J. Virol. 69:1995;6609-6617.
10. Emini E.A., et al. Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody. Nature. 355:1992;728-730.
11. Burton D.R. A vaccine for HIV type 1: the antibody perspective. Proc. Natl. Acad. Sci. USA. 94:1997;10018-10023.
12. Vancott T.C., et al. Immunogenicity and efficacy of HIV-1 envelope subunit vaccines in rhesus macaques. Girard M., Dodet B., et al. Onzième Colloque des Cent Gardes: retroviruses of human AIDS and related animal diseases, 27-29 October. 1997.
13. Connick E., et al. HIV-specific cellular and humoral responses to primary HIV infection. AIDS Res. Hum. Retrovir. 12:1996;1129-1140.
14. Baum L.L., et al. HIV-1 gp120-specific antibody-dependent cell-mediated cytotoxicity correlates with rate of disease progression. J. Immunol. 157:1996;2168-2173.
15. Rinaldo C., et al. High levels of antihuman immunodeficiency virus type 1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1 infected long-term nonprogressors. J. Virol. 69:1995;5838-5842.
16. Rowland-Jones S.L., McMichael A. Immune responses in HIV-exposed seronegatives: have they repelled the virus? Curr. Opin. Immunol. 7:1995;448-455.
17. Ogg G.S., et al. Quantitation of HIV-1-specific cytotoxic lymphocytes and plasma load of viral RNA. Science. 279:1998;2103-2106.
18. Borrow P., et al. Antiviral pressure exerted by HIV-1 specific cytotoxic lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nat. Med. 3:1997;205-211.
19. Rosenberg E.S., et al. Vigorous HIV-1 specific CD4+ T cell responses associated with control of viremia. Science. 278:1997;1447-1450.
20. Lehner T., et al. Protective mucosal immunity elicited by targeted iliac lymph node immunization with a subunit SIV envelope and core vaccine in macaques. Nat. Med. 2:1996;767-775.
21. Benson J., et al. Recombinant vaccine-induced protection against the highly pathogenic simian immunodeficiency virus SIVmac251. Dependence on route of challenge exposure. J. Virol. 72:1998;4170-4182.
22. Girard M et al., Immunization with an HIV-1 canarypox virus recombinant confers protection against genital challenge in chimpanzees. XI International Conference on AIDS. Vancouver, 1996 (Abstr We A.393).
23. Mazzoli S., et al. HIV-specific mucosal and cellular immunity in HIV-seronegative partners of HIV-seropositive individuals. Nat. Med. 3:1997;1250-1257.
24. Excler J.L., Plotkin S. The prime-boost concept applied to HIV preventive vaccines. AIDS. 11:(Suppl. A):1997;S127-S137.
25. Tartaglia J., et al. Canarypox virus-based vaccines: prime-boost strategies to induce cell-mediated and humoral immunity against HIV. AIDS Res. Hum. Retrovir. 14:(Suppl. 3):1998;S291-S298.
26. Barnett S.W., et al. Prime-boost immunization strategies against HIV. AIDS Res. Hum. Retrovir. 14:(Suppl. 3):1998;S299-S309.
27. Clements-Mann M.L., et al. HIV-1 immune responses induced by canarypox (ALVAC)-gp160MN, SF-2 rgp 120, or both vaccines in seronegative adults. J. Inf. Dis. 177:1998;1230-1246.
28. Zolla-Pazner S et al., Neutralization of syncytium-inducing primary isolates by sera from uninfected recipients of candidate HIV vaccines. J Inf Dis (in press).
29. Ferrari G., et al. Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers. Proc. Natl. Acad. Sci. USA. 94:1997;1396-1401.
30. Corey L., et al. Cytotoxic T cell and neutralizing antibody responses to human immunodeficiency virus type 1 envelope with a combination regimen. J. Inf. Dis. 177:1998;301-309.
31. Belshe RB et al., Rapid induction of HIV-1 immune responses by canarypox (ALVAC) HIV-1 and gp120 SF2 recombinant vaccines in uninfected volunteers. J. Inf. Dis. (in press).
32. Evans T et al., A canarypox vaccine expressing multiple HIV-1 genes (vCP300) elicits broad and durable CTL responses in seronegative volunteers (submitted for publication).
33. Cohen J. Novel campaign to test live HIV vaccine (news). Science. 277:1997;1035.
34. Desroziers R.C. Nonhuman primate models for AIDS vaccines. AIDS. 9:(Suppl. A):1995;S137-S141.
35. Baba T.W., et al. Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques. Science. 267:1995;1820-1825.
36. Cohen J. Weakened SIV vaccines still kills (news). Science. 278:1997;24-25.
37. Fouts T.R., et al. Neutralization of the human immunodeficiency virus type 1 primary isolated JR-FL by human monoclonal antibodies correlates with antibody binding to oligomeric form of the envelope glycoprotein complex. J. Virol. 71:1997;2779-2785.
38. Vancott T.C., et al. Antibodies with specificity to native gp120 and neutralization activity against primary human immunodeficiency virus type 1 isolates elicited by immunization with oligomeric gp160. J. Virol. 71:1997;4319-4330.
39. Rovinski B., et al. Induction of HIV type 1 neutralizing and env-CD4-blocking antibodies by immunization with genetically engineered HIV type 1-like particles containing unprocessed gp160 glycoproteins. AIDS Res. Hum. Retrovir. 11:1995;1187-1895.
40. Reitter J.N., Desrosiers R.C. Identification of replication-competent strains of simian immunodeficiency virus lacking multiple attachment sites for N-linked carbohydrates in variable regions 1 and 2 of the surface envelope proteins. J. Virol. 72:1998;5399-5407.
41. Kwong P.D., et al. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature. 393:1998;648-659.
42. Rizzuto C.D., et al. A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding. Science. 280:1998;1949-1953.
43. Muster T., et al. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J. Virol. 67:1993;6642-6647.
44. Tartaglia J., et al. Potential improvements for poxvirus-based immunization vehicles. Girard M., Dodet B., et al. Onzième Colloque des Cent Gardes: retroviruses of human AIDS and related animal diseases, 27-29 October 1997. 1997.
45. Donnelly J.J., et al. DNA vaccines. Annu. Rev. Immunol. 15:1997;617-648.
46. Frolov I., et al. Alphavirus-based expression vectors: Strategies and applications. Proc. Natl. Acad. Sci. USA. 93:1996;11371-11377.
47. Caley I.J., et al. Humoral, mucosal, and cellular immunity in response to a human immuno-deficiency virus type 1 immunogen expressed by a Venezuelan equine encephalitis virus vaccine vector. J. Virol. 71:1997;3031-3038.
48. Okada E., et al. Intranasal immunization of a DNA vaccine with IL-12 and granulocyte-macrophage stimulating factor (GM-CSF)-expressing plasmid in liposomes induces strong mucosal and cell-mediated immune responses against HIV-1 antigens. J. Immunol. 159:1997;3638-3647.
49. Sizemore D.R., Branstrom A.A., Sadoff X. Attenuated Shigella as a DNA delivery vehicles for DNA-mediated immunization. Science. 270:1995;299-302.
50. Darji A., et al. Oral somatic transgene vaccination using attenuated S. typhimurium. Cell. 91:1997;765-775.